LTB4R and pancreatic neoplasm: Treatment of pancreatic cancer cells with the common BLT1 and BLT2 agonist LTB4 caused an additional growth advantage when compared with cells treated with Compound A or B. Proliferation was measured by cell counting and MTT assay.